FDA warned telehealth seller AM RX that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.
What happened
FDA reviewed the company's website, getamrx.com, in March 2026 and found it offering compounded semaglutide and tirzepatide drug products. The site showed product labels reading "AM Rx," suggesting AM RX made the drugs when it did not, and used claims linking the compounded drugs to the FDA-approved products Ozempic and Wegovy. FDA says those statements falsely imply the compounded products are FDA-approved or have been evaluated for safety and effectiveness.
What FDA found
The website's product labels carry the name "AM Rx," which tells buyers AM RX made the drugs when it did not.
21 C.F.R. § 201.1(h)(2); FD&C Act § 502(a) [21 U.S.C. § 352(a)]The site says its compounded semaglutide is the active ingredient in Ozempic and Wegovy, implying the compounded drugs are FDA-approved when they are not.
FD&C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The site markets compounded semaglutide as though it had been reviewed for safety and effectiveness, which compounded drugs have not.
FD&C Act § 502(bb) [21 U.S.C. § 352(bb)]Because the products are misbranded, shipping them across state lines is a prohibited act.
FD&C Act § 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA tells the company to email a written response to its Office of Compounding Quality and Compliance within 15 business days, listing the steps taken to fix the violations and prevent them from recurring. The response should name the entities that make the compounded drugs, include sample labeling, and show how the misleading website claims were corrected or removed.
Who should pay attention
- telehealth platforms selling compounded GLP-1 drugs
- compounding pharmacies whose products are resold by online marketers
- marketing and compliance teams that draft drug claims for websites
This is a summary. Read the original letter on fda.gov.